The role of erbB-2 and its ligands in growth control of malignant breast epithelium

Ruth Lupu, Robert B. Dickson, Marc E Lippman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The erbB-2 (HER-2, neu) protooncogene is overexpressed on the surface of about 25% of human breast cancers. It is homologous to epidermal growth factor receptor and a putative growth factor receptor. Overexpression in breast, ovarian and gastric cancers is associated with a worse prognosis. We have recently discovered two ligands for this receptor. They both induce receptor phosphorylation. At low concentrations both induce clonogenic growth of overexpressing cells; at higher concentrations both are growth inhibitory. Both can overcome the inhibitory effects of both monoclonal antibodies directed against the ligand binding site and soluble extracellular domain. These ligands may form an attractive basis for antitumor therapy.

Original languageEnglish
Pages (from-to)229-236
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume43
Issue number1-3
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Breast
Epithelium
Ligands
Growth
Breast Neoplasms
Phosphorylation
Growth Factor Receptors
Epidermal Growth Factor Receptor
Ovarian Neoplasms
Stomach Neoplasms
Binding Sites
Monoclonal Antibodies
Cells
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

The role of erbB-2 and its ligands in growth control of malignant breast epithelium. / Lupu, Ruth; Dickson, Robert B.; Lippman, Marc E.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 43, No. 1-3, 01.01.1992, p. 229-236.

Research output: Contribution to journalArticle

Lupu, Ruth ; Dickson, Robert B. ; Lippman, Marc E. / The role of erbB-2 and its ligands in growth control of malignant breast epithelium. In: Journal of Steroid Biochemistry and Molecular Biology. 1992 ; Vol. 43, No. 1-3. pp. 229-236.
@article{d6a573d50101405397b29e5fc138791b,
title = "The role of erbB-2 and its ligands in growth control of malignant breast epithelium",
abstract = "The erbB-2 (HER-2, neu) protooncogene is overexpressed on the surface of about 25{\%} of human breast cancers. It is homologous to epidermal growth factor receptor and a putative growth factor receptor. Overexpression in breast, ovarian and gastric cancers is associated with a worse prognosis. We have recently discovered two ligands for this receptor. They both induce receptor phosphorylation. At low concentrations both induce clonogenic growth of overexpressing cells; at higher concentrations both are growth inhibitory. Both can overcome the inhibitory effects of both monoclonal antibodies directed against the ligand binding site and soluble extracellular domain. These ligands may form an attractive basis for antitumor therapy.",
author = "Ruth Lupu and Dickson, {Robert B.} and Lippman, {Marc E}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0960-0760(92)90212-2",
language = "English",
volume = "43",
pages = "229--236",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-3",

}

TY - JOUR

T1 - The role of erbB-2 and its ligands in growth control of malignant breast epithelium

AU - Lupu, Ruth

AU - Dickson, Robert B.

AU - Lippman, Marc E

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The erbB-2 (HER-2, neu) protooncogene is overexpressed on the surface of about 25% of human breast cancers. It is homologous to epidermal growth factor receptor and a putative growth factor receptor. Overexpression in breast, ovarian and gastric cancers is associated with a worse prognosis. We have recently discovered two ligands for this receptor. They both induce receptor phosphorylation. At low concentrations both induce clonogenic growth of overexpressing cells; at higher concentrations both are growth inhibitory. Both can overcome the inhibitory effects of both monoclonal antibodies directed against the ligand binding site and soluble extracellular domain. These ligands may form an attractive basis for antitumor therapy.

AB - The erbB-2 (HER-2, neu) protooncogene is overexpressed on the surface of about 25% of human breast cancers. It is homologous to epidermal growth factor receptor and a putative growth factor receptor. Overexpression in breast, ovarian and gastric cancers is associated with a worse prognosis. We have recently discovered two ligands for this receptor. They both induce receptor phosphorylation. At low concentrations both induce clonogenic growth of overexpressing cells; at higher concentrations both are growth inhibitory. Both can overcome the inhibitory effects of both monoclonal antibodies directed against the ligand binding site and soluble extracellular domain. These ligands may form an attractive basis for antitumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026644686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026644686&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(92)90212-2

DO - 10.1016/0960-0760(92)90212-2

M3 - Article

C2 - 1356015

AN - SCOPUS:0026644686

VL - 43

SP - 229

EP - 236

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-3

ER -